ALEMBICLTDNSEAlembic Limited· PharmaceuticalsHighNeutral
Announced Tue, 13 May · 17:33 IST

Alembic Limited has informed the Exchange regarding Outcome of Board Meeting held on May 13, 2025.

Emphasis Of MatterRevenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF

ALEMBICLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Alembic Limited's board approved audited consolidated and standalone results for Q4 and FY ended March 31, 2025. Consolidated revenue from operations jumped to Rs. 22,189 lakhs in FY25 from Rs. 15,749 lakhs in FY24, a growth of about 41%, driven largely by the Real Estate segment (Rs. 18,967 lakhs vs Rs. 12,574 lakhs). Consolidated net profit (after share of associate Alembic Pharmaceuticals) rose to Rs. 31,068 lakhs from Rs. 26,862 lakhs, while standalone net profit surged to Rs. 14,195 lakhs from Rs. 9,289 lakhs, a jump of nearly 53%. Standalone EPS improved to Rs. 5.53 from Rs. 3.62. The board recommended a dividend of Rs. 2.40 per share (120%) on a Rs. 2 face value, unchanged from the previous year. The auditors CNK & Associates LLP issued an unmodified opinion on both sets of results, but included an emphasis of matter on a disputed electricity duty liability (Rs. 2,052 lakhs provisioned, Rs. 3,500 lakhs deposited with the Supreme Court).

Likely market impact

Strong revenue and profit growth, especially in real estate, and a maintained 120% dividend are positive for shareholders. However, the ongoing electricity duty dispute remains a legal overhang, even though the auditor's opinion is clean.